Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Proactive strategies and sustained delivery advance glaucoma care | Ophthalmology Times
(Image Credit: AdobeStock/Monkey Business) Proactive strategies in glaucoma care, including minimally invasive glaucoma surgery (MIGS) and physician decision-making, were the focus of a recent Ophthalmology Times Case-Based Roundtable, moderated by Sahar Bedrood, MD, PhD, a glaucoma specialist at Advanced Vision…
STAAR postpones Alcon merger vote, Broadwood calls for removal of board members | Ophthalmology Times
(Image Credit: AdobeStock/izzuan) The proposed merger between Alcon and STAAR Surgical continues to muddy as STAAR and Alcon have decided to postpone the Special Meeting of Stockholders that was scheduled for October 23, 2025, until November 6, 2025.1 The delay in…
Novel therapy for incision-free keratoconus: Q&A with Gloria B. Chiu, OD, FAAO, FSLS | Ophthalmology Times
The FDA-approved, incision-free Epioxa therapy is changing the landscape of keratoconus care, explains Gloria B. Chiu, OD, FAAO, FSLS. (Image credit: AdobeStock/Zarina Lukash) Glaukos recently obtained FDA clearance for Epioxa, a topical, incision-free therapy for keratoconus that preserves the corneal epithelium.1 The…
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study | Ophthalmology Times
(Image Credit: AdobeStock/Minerva Studio) Nanoscope Therapeutics has released positive 3-year follow-up data from its REMAIN study, the long-term extension of the phase 2b/3 RESTORE trial (NCT04945772) evaluating MCO-010 in retinitis pigmentosa (RP). RESTORE was a multicenter, randomized, double-masked, sham-controlled, dose-ranging study evaluating 2 dose…
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment | Ophthalmology Times
The FDA has requested additional evidence for Sydnexis’ SYD-101, a 0.01% atropine eye drop aimed at slowing myopia progression in children, despite positive outcomes from the STAR clinical trial. (Image credit: Ophthalmology Times) The FDA has sent a complete response…
Periorbital rejuvenation: Past, present, and next | Ophthalmology Times
(Image Credit: AdobeStock/Alessandro Grandini) The aesthetic treatment of the periorbital region has evolved significantly, shaped by centuries of innovation and driven by the desire to understand anatomy and how it is affected by aging. Among the earliest documented advancements in…
AAO 2025: Margaret A. Chang, MD, MS, highlights OTX-TKI’s impact on retinal fluid | Ophthalmology Times
Margaret A. Chang, MD, MS, presented updates from the HELIOS Phase 1 trial of OTX-TKI, a sustained-release formulation of the tyrosine kinase inhibitor, axitinib, for the treatment of diabetic retinopathy (DR), at the American Academy of Ophthalmology 2025 annual meeting,…
AAO 2025: Retinal manifestations of antipsychotic medications | Ophthalmology Times
Sharon Fekrat, MD, FACS, FASRS, shared insights at the American Academy of Ophthalmology (AAO) 2025 meeting in Orlando on the retinal manifestations of antipsychotic medications—a topic with important clinical implications for retina specialists. Antipsychotic drugs, used to treat conditions such…
The mechanics of presbyopia: From muscle movement to functional vision | Ophthalmology Times
(Image Credit: AdobeStock) Presbyopia-correcting eye drops share a common mechanism: They are miotic agents designed to create a smaller pupil. The power of the pupil to extend depth of focus is impressive, as observed in patients with smaller pupils who…
Starting from scratch on neovascular age-related macular degeneration | Ophthalmology Times
(Image Credit: AdobeStock) Luis Arias, MD; and Paolo Lanzetta, MD, recently found themselves on opposite sides of the debate table regarding the value of gene therapy to treat neovascular age-related macular degeneration (nAMD) at the 16th Annual Congress on Controversies…